Revolution Medicines is in a powerful sustained uptrend, with the stock surging 408.8% over the past year and currently trading at 98.0% of its 52-week range (close to the $193.10 high). The price sits at $189.24, just 2.0% below the 52-week high, indicating strong momentum and bullish sentiment, though near-term overextension is a risk. The 1-year relative strength versus SPY is +389.7%, confirming exceptional outperformance driven by clinical catalysts. Short-term momentum is accelerating sharply: the 1-month price change is +25.1% and the 3-month change is +90.9%, far outpacing the S&P 500's -1.25% and +13.6% respectively. This divergence from the broader market suggests company-specific catalysts are driving the move, with the April 2026 Phase 3 data acting as a major inflection point. The 1-month relative strength of +26.3% indicates continued buying pressure, though the rapid ascent could invite profit-taking. Key support lies at the 52-week low of $34.00, a distant 82% below current levels, while resistance is at the 52-week high of $193.10. A breakout above $193.10 would signal further upside and confirm the uptrend's extension, while a breakdown below recent support near $150 (the May-June consolidation zone) could indicate a pullback. The stock's beta of 1.376 implies 37.6% more volatility than the market, meaning outsized moves in both directions, which is consistent with its biotech risk profile and requires careful position sizing.

Revolution Medicines is a pre-revenue clinical-stage biotech with zero product revenue in the most recent quarter (Q4 2025) and only $7.0 million in collaboration revenue for the full year. The company has no recurring revenue stream, and its growth trajectory is binary, dependent on clinical trial outcomes and regulatory approvals. The Q4 2025 net loss was -$364.9 million, widening from -$194.6 million in Q4 2024, reflecting increased R&D spending (R&D expense of $292.6 million in Q4 2025 vs. $188.1 million a year ago) as the pipeline advances. The company is deeply unprofitable, with a trailing twelve-month net loss of -$1.13 billion and negative gross margins (gross profit of -$4.7 million in Q4 2025). Operating margins are deeply negative, with operating income of -$361.6 million in Q4 2025, and the net margin is effectively zero due to no revenue. The company's balance sheet shows a current ratio of 7.14 and cash of $388.6 million as of Q4 2025, but it is burning cash rapidly: free cash flow was -$276.2 million in Q4 2025 and -$913.7 million on a TTM basis. The debt-to-equity ratio is low at 0.097, but the company relies on equity financing, as evidenced by the $2.2 billion public offering in April 2026. ROE is deeply negative at -69.3%, reflecting persistent losses. The company's financial health depends on its ability to raise capital and achieve regulatory milestones, making it a high-risk investment.